Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × nintedanib × Thoracic × Clear all

Phase

Status

Sponsor Class

OTHER 11 INDUSTRY 9 OTHER_GOV 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1 Thoracic 1 Sarcoma 1 Other solid neoplasm 1 Head & Neck 1 Gynecologic 1 Genitourinary 1

Conditions

Mesothelioma, Malignant 1

Interventions

Cisplatin 38 Carboplatin 38 Paclitaxel 32 Radiotherapy 29 Docetaxel 17 Etoposide 16 Pemetrexed 15 Gemcitabine 15 Bevacizumab 10 Radiosurgery 9 Magnetic Resonance Spectroscopy 8 durvalumab 7 Taxes 7 Ramucirumab 6 Erlotinib Hydrochloride 6 Cetuximab 6 pembrolizumab 5 Specimen Handling 5 Irinotecan 5 Gene Expression Profiling 5 Filgrastim 5 cediranib 4 Vinorelbine 4 Polymerase Chain Reaction 4 Neoadjuvant Therapy 4 Chemotherapy, Adjuvant 4 Amplified Fragment Length Polymorphism Analysis 4 tremelimumab 3 osimertinib 3 Watchful Waiting 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02863055 2025-09-19

NEMO

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Terminated

Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡